Repositorio
Institucional

Chow, Clara Kayei

Nguyen, Tu Ngoc

Marschner, Simone

Diaz, Rafael

Rahman, Omar

Avezum, Alvaro

Lear, Scott A.

Teo, Koon

Yeates, Karen E.

Lanas, Fernando

Li, Wei

Hu, Bo

Lopez-Jaramillo, Patricio

Gupta, Rajeev

Kumar, Rajesh

Mony, Prem K.

Bahonar, Ahmad

Yusoff, Khalid

Khatib, Rasha

Kazmi, Khawar

Dans, Antonio L.

Zatonska, Katarzyna

Alhabib, Khalid F.

Kruger, Iolanthe Marike

Rosengren, Annika

Gulec, Sadi

Yusufali, Afzalhussein

Chifamba, Jephat

Rangarajan, Sumathy

McKee, Martin

Yusuf, Salim

Availability and affordability of medicines and cardiovascular outcomes in 21 high-income, middle-income and low-income countries

BMJ PUBLISHING GROUP

BMJ GLOBAL HEALTH

en

artículo original

acceso abierto

SY cuenta con el apoyo de la cátedra Mary W Burke de la Heart and Stroke Foundation de Ontario. El estudio PURE es un estudio iniciado por investigadores y financiado por el Population Health Research Institute, el Hamilton Health Sciences Research Institute (HHSRI), los Canadian Institutes of Health Research, Heart and Stroke Foundation de Ontario, con el apoyo de la Strategy for Patient Oriented Research de los Canadian Institutes of Health Research, a través de la Ontario SPOR Support Unit, así como del Ontario Ministry of Health and Long-Term Care y mediante subvenciones sin restricciones de varias compañías farmacéuticas (con importantes contribuciones de AstraZeneca (Canadá), Sanofi-Aventis (Francia y Canadá), Boehringer Ingelheim (Alemania y Canadá), Servier y GlaxoSmithKline), y contribuciones adicionales de Novartis y King Pharma, y ​​de varias organizaciones nacionales o locales de los países participantes. Entre ellas se incluyen Argentina: Fundación ECLA (Estudios Clínicos Latinoamericanos); Bangladesh: Independent University, Bangladesh y Mitra and Associates; Brasil: Unilever Health Institute, Brasil; Canadá: este estudio fue financiado mediante una subvención sin restricciones de Dairy Farmers of Canada y el National Dairy Council (EE. UU.), la Agencia de Salud Pública de Canadá y Champlain Cardiovascular Disease Prevention Network; Chile: Universidad de La Frontera [DI13-PE11]; China: Centro Nacional de Enfermedades Cardiovasculares y ThinkTank Research Center for Health Development; Colombia: Colciencias (subvención 6566-04-18062 y subvención 6517-777-58228); India: Consejo Indio de Investigación Médica; Malasia: Ministerio de Ciencia, Tecnología e Innovación de Malasia (número de subvención: 100-IRDC/BIOTEK 16/6/21 [13/2007] y 07-05-IFN-BPH 010), Ministerio de Educación Superior de Malasia (número de subvención: 600-RMI/LRGS/5/3 [2/2011]), Universiti Teknologi MARA, Universiti Kebangsaan Malaysia (UKM-Hejim-Komuniti-15-2010); territorio palestino ocupado: Organismo de Obras Públicas y Socorro de las Naciones Unidas para los Refugiados de Palestina en el Cercano Oriente, territorio palestino ocupado; Centro Internacional de Investigaciones para el Desarrollo, Canadá; Filipinas: Consejo Filipino para la Investigación y el Desarrollo en Salud; Polonia: Ministerio de Ciencia y Educación Superior de Polonia (número de subvención: 290/W-PURE/2008/0), Universidad Médica de Wroclaw; Arabia Saudita: Asociación Saudita del Corazón, Asociación Saudita de Gastroenterología, Hospital Dr. Mohammad Alfagih, Decanato de Investigación Científica en la Universidad Rey Saud, Riad, Arabia Saudita (número de grupo de investigación: RG-1436-013); Sudáfrica: Universidad del Noroeste, Sudáfrica y Programa de los Países Bajos para el Desarrollo Alternativo, Fundación Nacional de Investigación, Consejo de Investigación Médica de Sudáfrica, Asociación Sudafricana del Azúcar, Facultad de Ciencias de la Comunidad y la Salud; Suecia: Subvenciones del estado sueco en virtud del Acuerdo sobre investigación y educación de médicos; Fundación Sueca del Corazón y los Pulmones; Consejo Sueco de Investigación; Consejo Sueco para la Salud, la Vida Laboral y el Bienestar, Fundación de los Francmasones Rey Gustavo V y Reina Victoria, AFA Insurance; Turquía: Sociedad del Síndrome Metabólico, AstraZeneca, Sanofi Aventis; Emiratos Árabes Unidos: Premio Sheikh Hamdan Bin Rashid Al Maktoum para Ciencias Médicas y Autoridad de Salud de Dubái, Dubái.

SY is supported by the Mary W Burke endowed chair of the Heart and Stroke Foundation of Ontario. The PURE study is an investigator-initiated study that is funded by the Population Health Research Institute, Hamilton Health Sciences Research Institute (HHSRI), the Canadian Institutes of Health Research, Heart and Stroke Foundation of Ontario, Support from Canadian Institutes of Health Research's Strategy for Patient Oriented Research, through the Ontario SPOR Support Unit, as well as the Ontario Ministry of Health and Long-Term Care and through unrestricted grants from several pharmaceutical companies (with major contributions from AstraZeneca (Canada), Sanofi-Aventis (France and Canada), Boehringer Ingelheim (Germany and Canada), Servier, and GlaxoSmithKline), and additional contributions from Novartis and King Pharma and from various national or local organisations in participating countries. These include Argentina: Fundacion ECLA (Estudios Clinicos Latino America); Bangladesh: Independent University, Bangladesh and Mitra and Associates; Brazil: Unilever Health Institute, Brazil; Canada: this study was supported by an unrestricted grant from Dairy Farmers of Canada and the National Dairy Council (USA), Public Health Agency of Canada and Champlain Cardiovascular Disease Prevention Network; Chile: Universidad de La Frontera [DI13-PE11]; China: National Center for Cardiovascular Diseases and ThinkTank Research Center for Health Development; Colombia: Colciencias (grant 6566-04-18062 and grant 6517-777-58228); India: Indian Council of Medical Research; Malaysia: Ministry of Science, Technology and Innovation of Malaysia (grant number: 100-IRDC/BIOTEK 16/6/21 [13/2007], and 07-05-IFN-BPH 010), Ministry of Higher Education of Malaysia (grant number: 600-RMI/LRGS/5/3 [2/2011]), Universiti Teknologi MARA, Universiti Kebangsaan Malaysia (UKM-Hejim-Komuniti-15-2010); occupied Palestinian territory: the United Nations Relief and Works Agency for Palestine Refugees in the Near East, occupied Palestinian territory; International Development Research Centre, Canada; Philippines: Philippine Council for Health Research and Development; Poland: Polish Ministry of Science and Higher Education (grant number: 290/W-PURE/2008/0), Wroclaw Medical University; Saudi Arabia: Saudi Heart Association, Saudi Gastroenterology Association, Dr.Mohammad Alfagih Hospital, The Deanship of Scientific Research at King Saud University, Riyadh, Saudi Arabia (Research group number: RG -1436-013); South Africa: The North-West University, SA and Netherlands Programme for Alternative Development, National Research Foundation, Medical Research Council of South Africa, The South Africa Sugar Association, Faculty of Community and Health Sciences; Sweden: Grants from the Swedish state under the Agreement concerning research and education of doctors; the Swedish Heart and Lung Foundation; the Swedish Research Council; the Swedish Council for Health, Working Life and Welfare, King Gustaf V:s and Queen Victoria Freemason's Foundation, AFA Insurance; Turkey: Metabolic Syndrome Society, AstraZeneca, Sanofi Aventis; United Arab Emirates: Sheikh Hamdan Bin Rashid Al Maktoum Award For Medical Sciences and Dubai Health Authority, Dubai.

10.1136/bmjgh-2020-002640

pdf

epidemiology

health policy

prevention strategies

public health

treatment

epidemiología

política de salud

estrategias de prevención

salud pública

tratamiento

Salud Pública y Ambiental

WOS:000591350400001

acceso abierto

acceso abierto

pdf

Availability and affordability of medicines and cardiovascular outcomes in 21 high-income, middle-income and low-income countries

artículo original

version publicada

2059-7908

dorada

verde

Heart and Stroke

PHRI

CIHR

Ontario Ministry of Health and Long-Term Care

AstraZeneca Canada

Sanofi-Aventis France

Sanofi-Aventis Canada

Boehringer Ingelheim Germany

Boehringer Ingelheim Canada

Servier

GlaxoSmithKline

Novartis

Fundacion ECLA

ndependent University Bangladesh

Unilever Health Institute, Brazil

Canada: Dairy Farmers of Canada USA

Canada: National Dairy Council USA

Canada: Public Health Agency of Canada

Canada: Champlain Cardiovascular Disease Prevention Network

Chile: UFRO DI13-PE11

China: National Center for Cardiovascular Diseases and ThinkTank Research Center for Health Development

Colciencias 6566-04-18062

ColCiencias 6517-777-58228

Indian Council of Medical Research

MOSTI 100-IRDC/BIOTEK 16/6/21 13/2007

MOSTI 07-05-IFN-BPH 010

MOHE 600-RMI/LRGS/5/3 2/2011

Universiti Teknologi MARA

Universiti Kebangsaan Malaysia UKM-Hejim-Komuniti-15-2010

occupied Palestinian territory: the United Nations Relief and Works Agency for Palestine Refugees in the Near East, occupied Palestinian territory

IDRC

NAUKA, Wroclaw Medical University 290/W-PURE/2008/0

Saudi Heart Association

Saudi Gastroenterology Association

Dr.Mohammad Alfagih Hospital

The Deanship of Scientific Research at King Saud University, Riyadh RG -1436-013

The North-West University

Netherlands Programme for Alternative Development

National Research Foundation

Medical Research Council of South Africa

The South Africa Sugar Association

Faculty of Community and Health Sciences

Swedish state under the Agreement concerning research and education of doctors

Swedish Heart and Lung Foundation

Swedish Research Council

Swedish Council for Health, Working Life and Welfare

AFA Insurance

Metabolic Syndrome Society

AstraZeneca

Sanofi Aventis

United Arab Emirates: Sheikh Hamdan Bin Rashid Al Maktoum Award For Medical Sciences,

Dubai Health Authority, Dubai

King Pharma

Bangladesh: Mitra and Associates

Philippine Council for Health Research and Development

Hamilton Health Sciences Research Institute HHSRI

King Gustaf V:s and Queen Victoria Freemason's Foundation